Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

July 1, 2010

View Archives Issues

  • New Money, Old Parasite

    Every year about this time, I see a couple of unhappy local residents who present with an intensely pruritic, erythematous papular mystery rash. In contrast to flea bites, which are simple raised papules, the lesions seem umbilicated or have a central bite mark.
  • Rifaximin Tablets (Xifaxan®)

    A rifamycin antibacterial agent has been approved for treating patients with hepatic encephalopathy (HE). Rifaximin is a minimally absorbed oral antimicrobial that was originally approved in 2004 for the treatment of travelers' diarrhea caused by Escherichia coli. It is marketed by Salix Pharmaceuticals as Xifaxan®.
  • Reintroduction of TB Meds Following Hepatotoxicity

    Drug-related hepatotoxicity during treatment for tuberculosis is a common barrier to initiation of antimycobacterial. While most hepatotoxicity results in minimal to no gastrointestinal complaints, some patients experience significant nausea, anorexia, vomiting, or abdominal pain.
  • Pharmacology Watch: PPIs, Clostridium difficile, and Bone Fractures

    In this issue: New reports about proton pump inhibitors and the effects of gastric suppression, pioglitazone vs vitamin E for non-alcoholic steatohepatitis, metformin and vitamin B12 deficiency, and FDA Actions.